Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Comment by 90guppyon Apr 28, 2020 10:33am
71 Views
Post# 30961612

RE:RE:RE:RE:RE:RE:RE:RE:RE:are financials out now,

RE:RE:RE:RE:RE:RE:RE:RE:RE:are financials out now, in case you missed it, this  update is something new We are in discussions with medical and academic institutions in order to advance our program."

Once this happens research will accelerate and quickly get into phase 1 for medical and academic institutions have direct access to hospitals where covid patients are treated.

By the way the 1.3 million is enough to get the preliminary vaccine material tested for effectivity. Just to give you perspective, the Ebola vaccine was discovered by a team from the National Institute for Microbiology in Winnipeg, Canada using only $5.3 million funding from the Canadian govt, and the research team gotten that money in the span of 10 years.


<< Previous
Bullboard Posts
Next >>